Miglustat

FDA Approved: * April 17, 2018
Pharm Company: * AMERIGEN PHARMS LTD
Category: Enzymes

Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Miglustat 100 mg Oral Capsule
NDC: 10148-201
Labeler:
Cotherix, Inc.
Miglustat 100 mg Oral Capsule
NDC: 42799-708
Labeler:
Edenbridge Pharmaceuticals LLC.
Miglustat 100 mg Oral Capsule
NDC: 43975-310
Labeler:
Amerigen Pharmaceuticals Inc.
Miglustat 100 mg Oral Capsule
NDC: 51991-959
Labeler:
Breckenridge Pharmaceutical, Inc.

Related Brands

Drugs with the same active ingredients